ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will promote programs that support the glioblastoma (GBM) community during National Family Caregivers Month in November. Novocure will sponsor CURE magazine’s 2nd Annual GBM Heroes Recognition program, which honors those who have made a difference in the lives of people with the disease.
The event, which will be held in Scottsdale, Arizona, on Nov. 18, during the 21st Annual Scientific Meeting of the Society for Neuro-Oncology, will feature Fran Drescher – actress, author, health advocate, cancer survivor and founder of the Cancer Schmancer Movement, along with the four winners and the individuals who nominated them.
“Those in the GBM community are incredibly supportive of one another, and we take pride in our efforts to recognize their contributions,” said Mike Hennessy Jr., President of CURE Media Group. “We also appreciate the support that Novocure is providing not only to this event, but their continued commitment to the GBM community.”
During National Family Caregivers Month, Novocure will also offer new content on its online resource, GBMCommunity.com. The website features a mosaic of videos and images from people affected by GBM, offering messages of hope and inspiration, and encouraging others to share their voices. Novocure also will sponsor and participate in five advocacy and locally led walks from California to New York in November.
“Novocure recognizes the integral role that caregivers play in their loved one’s life as they face this devastating disease,” said Pritesh Shah, Novocure’s Senior Vice President, Americas. “It’s important that we honor the commitment of these caregivers and also provide them with space where they can hear and learn from others who may be on a similar journey.”
Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit novocure.com or follow us at www.twitter.com/novocure.
Glioblastoma, also called glioblastoma multiforme, or GBM, is a type of primary brain cancer. This means that GBM tumors begin in the brain, rather than traveling to the brain from other parts of the body, such as the lungs or breasts. GBM is the most common type of primary brain cancer in adults. It is more likely to appear in adults than children and to affect men than women.
Media and Investor Contact:
Ashley Cordova, 212-767-7558